Jak, sure. TAUG does not have any sales. But if you read the press releases they have multiple merge possibilities. In fact, I wouldn't be surprised if several merge candidates end up working with Seth's friends, who also have financed DECN.
I do not expect a merge to be agreed upon until TAUG is fully current and the litigation is disposed of.
Keep in mind that Seth has been working with these guys on several other deals that have fantastic potential. TAUG will be a clean reporting company and a great opportunity for a private company to do a reverse merger. Considering a SR Director of Pfizer is assisting vetting merger partners I put the chances of success as good.
DECN is in a Muli Billion dollar business and has a product, the sales are dismal. They have a CEO who has racked up 40 million in loses and wiped past shareholders out. He has been a Defendant in a shareholder lawsuit that shareholders won nearly 10 million dollars.
He is not able to provide audited financials, submits filings with simple errors, constantly changes filings when message board posters reveal the mistakes
The business model was Shasta's not his, his first attorney seems to be loaded with options. There does not seem to be any interest by any big pharma.
And what kind of a CEO tries to bribe another CEO with shares, asks a shareholder to s=disseminate an article that he is editing, and makes comments like he would Lay the CFO of TAUG if Seth wanted him to
good luck, I doubt he will be there long and hopefully the company is sold.
News 
Market Data 
Discover 
AI
